Vaccines for Enteric Diseases

16-18 October 2019, CHUV, University of Lausanne, Lausanne, Switzerland

  • Increase font size
  • Default font size
  • Decrease font size

Day One

Final Conference Programme | Wednesday 16th October 2019

08.00 onwards
Registration

08.55-09.00
Welcome & Opening Remarks

SESSION 1:
OPENING PLENARY SESSION

Moderator: Mike Levine (University of Maryland, Baltimore, Maryland, USA)

09.00-09.30
‘How could licensure and impact of enteric vaccines be accelerated?’

Birgitte Giersing
(WHO, Geneva, Switzerland)

09.30-10.00
‘Enteric Vaccines the PATHway forward’

Fred Cassels
(PATH, Washington DC, USA)

10.00-10.30
‘The importance of vaccine herd protection in the oral cholera vaccine story’
John D. Clemens
(icdrr,b, Dhaka, Bangladesh)

10.30-11.00
Coffee Break & Poster Session Set-Up

SESSION 2:
STANDARDISATION/BURDEN/SURVEILLANCE

Moderator: Fred Cassels (PATH, Washington DC, USA)

11.00-11.20
‘Standardisation of new enteric vaccines’
Sjoerd Rijpkema1, Fang Gao1, Peter Rigsby3, Jason Hockley3, Eleanor Atkinson3, Carolyn Swann2, Kay Lockyer1, Alastair Logan1 and Barbara Bolgiano1
(1 Division of Bacteriology, 2 Biostatistics and 3 Laboratory for Molecular Structure, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, UK)

11.20-11.40
‘Etiology of diarrhea requiring hospitalization in children under 5: Results from the first two years of the WHO-coordinated Global Pediatric Diarrhea Surveillance network, 2017-2018’
James A. Platts-Mills1 on behalf of the WHO-coordinated Global Pediatric Diarrhea Surveillance (GDPS) network
(1 Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, USA)

11.40-12.00
‘Recent findings from the World Health Organization-coordinated Global Rotavirus Surveillance Network’
Adam Lauren Cohen
(WHO, Geneva, Switzerland)

12.00-12.20
‘Geographic variation in diarrhoea mortality and treatment in low- and middle-income countries, 2000-2017’
Kirsten Wiens
(University of Washington, Seattle, Washington, USA)

12.20-12.40
‘The etiologic landscape and clinical outcomes of moderate-to-severe diarrhea among children under five in three sub-Saharan African countries post-rotavirus vaccine introduction: The Vaccine Impact on Diarrhea in Africa (VIDA) Study’
Karen L. Kotloff1,2, M. Jahangir Hossain3, Joquina Chiquita M. Jones3, Syed M.A. Zaman3, Martin Antonio3, Adama M. Keita4, Doh Sanogo4, Boubou Tamboura4, Samba O. Sow4, Richard Omore5, John B. Ochieng5, Jennifer Verani6, Marc-Alain Widdowson6, Jacqueline Tate7, Umesh Parashar7, Dilruba Nasrin1, Anna Roose1,2, Irene Kasumba1, William C. Blackwelder2, Helen Powel1,2, Milagritos Tapia11,2, Eric Houpt8, James Platts-Mills8 and Sharon M. Tennant1
(1 Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA; 2 Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, USA; 3 Medical Research Council Unit The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia; 4 Centre pour le Développement des Vaccins du Mali (CVD-Mali), Bamako, Mali; 5 Kenya Medical Research Institute/Center for Global Health Research (KEMRI-CGHR), Kisumu, Kenya; 6 Division of Global Health Protection, Kenya Office of the US Centers for Disease Control and Prevention (CDC), Nairobi, Kenya; 7 Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, CDC, Atlanta, Georgia, USA; 8 Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, Virginia, USA)

12.40-13.30
Lunch Break & Poster Session

SESSION 3:
CLINICAL ETEC VACCINE TRIALS

Moderators: Ann-Mari Svennerholm (University of Gothenburg, Gothenburg, Sweden) and Lou Bourgeois (PATH, Washington DC, USA)

13.30-13.40
‘Overview: ETEC vaccines in clinical trials (current or in planning)’

Lou Bourgeois
(PATH, Washington DC, USA)

13.40-14.00
‘Evaluation of the safety and immunogenicity of the oral inactivated enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants in a double-blind, randomized, placebo-controlled Phase I/II trial’

Firdausi Qadri1, Taufiqur R. Bhuiyan1, Marjahan Akhtar1, Anna Lundgren2, Nils Carlin3, A. Louis Bourgeois4, Nicole Maier4, Alan Fix4, Thomas Wierzba4, Richard I. Walker4 and Ann-Mari Svennerholm2
(1 icddr,b (International Center for Diarrhoeal Disease Research, Bangladesh), Dhaka, Bangladesh; 2 GUVAX, Gothenburg University Vaccine Research Institute, Dept. of Microbiology and Immunology, Inst. of Biomedicine, University of Gothenburg, Sweden; 3 Scandinavian Biopharma, Solna, Sweden; 4 PATH, Washington, DC, USA)

14.00-14.20
‘T cell responses induced by the oral inactivated ETEC vaccine ETVAX given with or without dmLT adjuvant’

Anna Lundgren1, Marjahan Akhtar2, Joanna Kaim1, Ana Cardeno1, Firdausi Qadri2 and Ann-Mari Svennerholm1
(1 University of Gothenburg Vaccine Research Institute, Sahlgrenska Academy, Sweden; 2 icddr,b (International Centre for Diarrhoeal Disease Research, Bangladesh), Dhaka, Bangladesh)

14.20-14.50
‘Evaluation of the oral etvax® vaccine against ETEC diarrhoea among finnish travellers to west-africa (oev-123 trial)’

Anu Kantele
(Meilahti Vaccination Research Center, MeVac, Helsinki University Hospital and University of Helsinki, Helsinki, Finland)

14.50-15.05
‘A Phase 1 dose-escalating study of a prototype CS6 subunit vaccine with a modified heat-labile enterotoxin from Enterotoxigenic Escherichia coli (ETEC)’

T.K. Lee1, C.K. Porter1, R.L. Gutierrez1, K. Jaep1,2, S.T. Poole1,2, A.B. Lane3, M. Hamer4, A.D. Vazquez4, M.S. Riddle5, M. Maciel Jr.1,2, K.E. Dori1,2, L. Yang1, A.N. Alcala1,2, D.R. Tribble5, R. Erdem6, N. Maier6, A.L. Bourgeois6 and M.G. Prouty1
(1 Naval Medical Research Center, Silver Spring, Maryland, USA; 2 Henry M. Jackson Foundation, Bethesda, Maryland, USA; 3 Walter Reed National Military Medical Center, Bethesda, Maryland, USA; 4 Walter Reed Army Institute of Research, Silver Spring, Maryland, USA; 5 Uniformed Services University of the Health Sciences, Bethesda, Maryland; 6 PATH, Washington, D.C., USA)

15.05-15.20
‘Serological and α4β7+ antibody-secreting cell responses after intramuscular immunization with CssBA, a CS6-subunit based enterotoxigenic E. coli vaccine candidate, and LT(R192G/L211A) as adjuvant’

Milton Maciel Jr.1,2, Stefanie Trop1,2, Aaron Kim1,2, Elizabeth Ward1,2, Zuzana Villar1,2, Tida K. Lee2, kayla Jaep1,2, Chad Porter2, Steven Poole1,2 and Michael G. Prouty2
(1 Henry M. Jackson Foundation, Bethesda, Maryland, USA; 2 Naval Medical Research Center, Silver Spring, Maryland, USA)

15.20-15.40
General Discussion on Clinical Trials

15.40-16.00
Tea Break & Poster Session

SESSION 4:
ENTERIC VACCINES FRONTEIRS

Moderators: Kevin Killeen (Matrivax Inc., Boston, Massachusetts, USA) and Elizabeth Norton (Tulane University, New Orleans, Louisiana, USA)

16.00-16.20
‘Update on CVD vaccines to prevent invasive Salmonella disease’

M. Levine
(University of Maryland, Baltimore, Maryland, USA)

16.20-16.40
‘Overview: Mucosal vaccines and adjuvants for enteric infections’

Jan Holmgren
(University of Gothenburg, Gothenburg, Sweden)

16.40-17.00
‘Bimodal prophylactic and therapeutic vaccine candidate targeting C. difficile infection and relapse’

Kevin Killeen
(Matrivax Inc., Boston, Massachusetts, USA)

17.00-17.20
‘Determination of mucosal immune responses against an oral ETEC vaccine in infants’

Ann-Mari Svennerholm1, Anna Lundgren1, Marjahan Akhtar2, Richard Walker3, Lou Bourgeois3 and Firdausi Qadri2
(1 University of Gothenburg, Gothenburg, Sweden; 2 Infectious Diseases Division, icddr,b (International Center for Diarrhoeal Disease Research, Bangladesh), Dhaka, Bangladesh; 3 PATH, Washington, DC, USA)

17.20-17.35
‘MecVax, a broadly protective subunit vaccine against enterotoxigenic Escherichia coli (ETEC) diarrhea’

Hyesuk Seo1,3, Xiaosai Ruan1, Qiangde Duan1, Carolina Garcia1, David A. Sack2 and Weiping Zhang1,3
(1 Department of Diagnostic Medicine/Pathobiology, Kansas State University, Manhattan, Kansas, USA; 2 Department of International Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA; 3 Department of Pathobiology, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA)

17.35-17.50
‘Immunogenicity characterization and pre-clinical evaluation of a combo vaccine for Shigella and enterotoxigenic Escherichia coli (ETEC)’

Hyesuk Seo1, Shaghayegh Anvari1, Siqi Li1, Ti Lu1, David A. Sack2 and Weiping Zhang1
(1 University of Illinois at Urbana-Champaign, Department of Pathobiology, Urbana, Illinois, USA; 2 Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA)

17.50-18.05
‘Experience from developing clinical trial sites in Nepal: Challenges, Risks & Mitigation Strategies’

Tarun Saluja, Bo Mi Kim, Suchada Chinaworapong, Sue Kyoung Jo, T. Anh Wartel and Sushant Sahastrabuddhe
(International Vaccine Institute (IVI), Seoul, Republic of Korea)

 

VED 2019 Delegates

Login details will be supplied after you have registered for the event.


VED 2019 Sponsors

  • DNAvaccine.com
  • Scandinavian Biopharma
  • BioVAXX
  • Eveliqure
  • Vaccine Research Center
  • Takeda
  • PATH
  • NatureGeneTherapy.com
  • Sanofi Pasteur
  • Vaxart
  • Matrivax
  • hVIVO
  • Aldevron
  • Vismederi
  • LimmaTech Biologics

VED 2019 Downloads

VED 2019 Leaflet

VED 2019 Mailing List

Name
E-mail Address
What is 3+2-1?